| Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
pharmaceutical_companies:pfizer [2022/05/23 21:02]
liam [Payments to Media] | pharmaceutical_companies:pfizer [2023/01/10 17:37] (current)
liam [Payments to Individuals] |
|---|
| |
| The [[:Upjohn]] pharmaceutical company was started by William Erastus Upjohn in 1885 and was a research and industry pillar in Kalamazoo until its merger with the Swedish company [[:Pharmacia]] in 1995. The hybrid company was bought by [[:Pfizer]] in 2003.((https://web.archive.org/web/20200405200549/https://web.archive.org/web/20070928141332/http://www.kpl.gov/collections/LocalHistory/AllAbout/biography/Upjohn.aspx)) | The [[:Upjohn]] pharmaceutical company was started by William Erastus Upjohn in 1885 and was a research and industry pillar in Kalamazoo until its merger with the Swedish company [[:Pharmacia]] in 1995. The hybrid company was bought by [[:Pfizer]] in 2003.((https://web.archive.org/web/20200405200549/https://web.archive.org/web/20070928141332/http://www.kpl.gov/collections/LocalHistory/AllAbout/biography/Upjohn.aspx)) |
| | |
| | 1999 LA Times - BLOOMBERG NEWS ST. LOUIS |
| | (note Agent Orange - PCB chemical giant Monsanto reference as a drug company) |
| | |
| | Monsanto Co. and rival drug maker Pharmacia & Upjohn Inc. on Sunday agreed to merge in a $26.5-billion stock transaction and sell off part of the agriculture business that helped drag Monsanto’s share price down 12% this year.((https://web.archive.org/web/20200804090911/https://www.latimes.com/archives/la-xpm-1999-dec-20-fi-45727-story.html)) |
| | |
| | Press Release - Pfizer Inc and Pharmacia Corporation began operating as a unified company on April 16, 2003, forging one of the world's fastest-growing and most valuable companies. With a research and development budget of $7.1 billion in 2003, the new Pfizer is now the world's leading research-based pharmaceutical company.((https://web.archive.org/web/20130820091420/https://www.pfizer.com/about/history/pfizer_pharmacia)) |
| |
| In 1952 two Upjohn biochemists, Dury Peterson and Herb Murray announced that they were able to introduce this crucial oxygen atom by fermentation of the [[:steroid progesterone]] with the mold Aspergillus nigercans. Over the next several years a group of chemists headed by John Hogg developed a process for preparing cortisone from the soybean steroid stigmasterol. The microbiological oxygenation is a key step in this process. [[:Monsanto]] was part of the acquisition and divesting scheme at Pfizer and ties to the soy interest.((https://web.archive.org/web/20110205152913/http://en.wikipedia.org/wiki/Upjohn)) | In 1952 two Upjohn biochemists, Dury Peterson and Herb Murray announced that they were able to introduce this crucial oxygen atom by fermentation of the [[:steroid progesterone]] with the mold Aspergillus nigercans. Over the next several years a group of chemists headed by John Hogg developed a process for preparing cortisone from the soybean steroid stigmasterol. The microbiological oxygenation is a key step in this process. [[:Monsanto]] was part of the acquisition and divesting scheme at Pfizer and ties to the soy interest.((https://web.archive.org/web/20110205152913/http://en.wikipedia.org/wiki/Upjohn)) |
| Importantly, BNT162b2 induced potent SARS-CoV-2 neutralizing antibodies in vaccinated-macaques, and viral antigen-specific CD4+ and CD8+ T cells. Rhesus macaques (2-4-year-old males) were immunized by intramuscular (IM) immunization with 30 µg or 100 µg of BNT162b2 or saline control on Days 0 and 21 (2 doses). After two immunizations, neutralization titers were detectable in rhesus macaques sera with geometric mean titers of 962 (on Day 35 for the 30 µg group) or 1,689 (on Day 28 for the 100 µg group). Neutralizing antibody titers persisted to at least day 56, with higher geometric mean titers (GMTs) than those in a panel of human convalescent sera. BNT162b2 vaccination elicited a high frequency of CD4+ T cells that produced IFN-ɣ, IL-2, and TNF-α, and almost no IL-4 producing CD4+ cells were detectable, indicating a TH1-biased response, which is an immune profile thought to promote vaccine safety. BNT162b2 also elicited spike-specific IFN-ɣ producing CD8+ T cell responses, which is thought to promote an anti-viral effect. | Importantly, BNT162b2 induced potent SARS-CoV-2 neutralizing antibodies in vaccinated-macaques, and viral antigen-specific CD4+ and CD8+ T cells. Rhesus macaques (2-4-year-old males) were immunized by intramuscular (IM) immunization with 30 µg or 100 µg of BNT162b2 or saline control on Days 0 and 21 (2 doses). After two immunizations, neutralization titers were detectable in rhesus macaques sera with geometric mean titers of 962 (on Day 35 for the 30 µg group) or 1,689 (on Day 28 for the 100 µg group). Neutralizing antibody titers persisted to at least day 56, with higher geometric mean titers (GMTs) than those in a panel of human convalescent sera. BNT162b2 vaccination elicited a high frequency of CD4+ T cells that produced IFN-ɣ, IL-2, and TNF-α, and almost no IL-4 producing CD4+ cells were detectable, indicating a TH1-biased response, which is an immune profile thought to promote vaccine safety. BNT162b2 also elicited spike-specific IFN-ɣ producing CD8+ T cell responses, which is thought to promote an anti-viral effect. |
| |
| In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, 1, or 5 µg) generated B-cell and T-cell immune responses in BALB/c mice, and SARS-CoV-2 pseudovirus neutralizing activity increased steadily to Day 28, the last day for which titers are reported. CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFNγ and IL-2, producing high levels of the TH1 cytokines but minute amounts of TH2 cytokines, suggesting a robust, TH1-biased T cell adaptive immune response. | In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, 1, or 5 µg) generated B-cell and T-cell immune responses in BALB/c mice, and SARS-CoV-2 pseudovirus neutralizing activity increased steadily to Day 28, the last day for which titers are reported. CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFNγ and IL-2, producing high levels of the TH1 cytokines but minute amounts of [[:TH2]] cytokines, suggesting a robust, TH1-biased T cell adaptive immune response. |
| |
| Many of these preclinical data and the Phase 1 clinical results contributed to the decision by Pfizer and BioNTech to commence the global (except for China) Phase 2/3 safety and efficacy portion of the clinical study to evaluate potential prevention of COVID-19 disease by BNT162b2. The Phase 2/3 study has enrolled over 25,000 participants 18 to 85 years of age in the U.S., Argentina and Brazil. Additional enrollment is planned in Germany, Turkey and South Africa. The study is an event-driven trial.((https://web.archive.org/web/20200918085932/https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-preclinical-studies-mrna)) | Many of these preclinical data and the Phase 1 clinical results contributed to the decision by Pfizer and BioNTech to commence the global (except for China) Phase 2/3 safety and efficacy portion of the clinical study to evaluate potential prevention of COVID-19 disease by BNT162b2. The Phase 2/3 study has enrolled over 25,000 participants 18 to 85 years of age in the U.S., Argentina and Brazil. Additional enrollment is planned in Germany, Turkey and South Africa. The study is an event-driven trial.((https://web.archive.org/web/20200918085932/https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-preclinical-studies-mrna)) |
| | [[:Dawn Bowdish]] | Research Award | Unknown | Funds for pneumonia research from [[:Ontario Lung Association]] and [[Pfizer]], and ASPIRE-Pfizer New Investigator Award.((Bowdish, D. M. E. (2013, February 11). //Dr. Dawn Bowdish receives a research award from the Ontario Lung Association and Pfizer Canada (and gets to attend a swanky event to receive it!).// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/AQqx1)) ((Bowdish, D. M. E. (2011, July 3). //Dawn wins ASPIRE-Pfizer New Investigator Award.// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/Dvre1)) | | | [[:Dawn Bowdish]] | Research Award | Unknown | Funds for pneumonia research from [[:Ontario Lung Association]] and [[Pfizer]], and ASPIRE-Pfizer New Investigator Award.((Bowdish, D. M. E. (2013, February 11). //Dr. Dawn Bowdish receives a research award from the Ontario Lung Association and Pfizer Canada (and gets to attend a swanky event to receive it!).// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/AQqx1)) ((Bowdish, D. M. E. (2011, July 3). //Dawn wins ASPIRE-Pfizer New Investigator Award.// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/Dvre1)) | |
| | [[:Richard Choi]] | Speakers Bureau/Honoraria/Consulting | Unknown | Disclosed during CardioVascUpdate presentation.((Verma, S., Bucci, C., Choi, R., & Gupta, A. (2020, June 12). //Navigating Vascular Protective Strategies in HighRisk Patients During the Current Era: Practical Applications.// CardioVascUpdate. https://web.archive.org/web/20210304170904/https://cardiovascupdate.ca/files/2020/CV%20Update%20Symposium-Presentation.pdf)) | | | [[:Richard Choi]] | Speakers Bureau/Honoraria/Consulting | Unknown | Disclosed during CardioVascUpdate presentation.((Verma, S., Bucci, C., Choi, R., & Gupta, A. (2020, June 12). //Navigating Vascular Protective Strategies in HighRisk Patients During the Current Era: Practical Applications.// CardioVascUpdate. https://web.archive.org/web/20210304170904/https://cardiovascupdate.ca/files/2020/CV%20Update%20Symposium-Presentation.pdf)) | |
| | | [[:Nigel Crawford]] | Research | Unknown | "Investigator on a number of epidemiological surveillance research and vaccine safety research. Funds received by employer", [[:Murdoch Children's Research Institute]] (MCRI).((//Australian Technical Advisory Group on Immunisation - Conflict of Interest.// Australia Government Department of Health and Aged Care. Retrieved October 24, 2022, from https://web.archive.org/web/20221024032912/https://www.health.gov.au/sites/default/files/atagi-conflict-of-interest-disclosures.pdf)) | |
| | [[:David Fisman]] | Honorarium | Unknown | Honorarium paid for advisory board meetings regarding COVID-19 related projects.((Fisman, D. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Science-Table_David-Fisman2.pdf)) | | | [[:David Fisman]] | Honorarium | Unknown | Honorarium paid for advisory board meetings regarding COVID-19 related projects.((Fisman, D. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Science-Table_David-Fisman2.pdf)) | |
| | [[:Soren Gantt]] | Grant | Unknown | Research grant paid to Gantt.((Lebatteux, D., Soudeyns, H., Boucoiran, I., Gantt, S., & Diallo, A. B. (2022). //Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures.// bioRxiv. Preprint. https://doi.org/10.1101/2022.02.07.479343)) | | | [[:Soren Gantt]] | Grant | Unknown | Research grant paid to Gantt.((Lebatteux, D., Soudeyns, H., Boucoiran, I., Gantt, S., & Diallo, A. B. (2022). //Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures.// bioRxiv. Preprint. https://doi.org/10.1101/2022.02.07.479343)) | |
| | [[:Kyla Hildebrand]] | Research | Unknown | Research funding for allergy study((Chan, E. S., Abrams, E. M., Hildebrand, K. J., & Watson, W. (2018). //Early introduction of foods to prevent food allergy.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0286-1)) | | | [[:Kyla Hildebrand]] | Research | Unknown | Research funding for allergy study((Chan, E. S., Abrams, E. M., Hildebrand, K. J., & Watson, W. (2018). //Early introduction of foods to prevent food allergy.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0286-1)) | |
| | | [[:Gilberto Lopes]] | Various | Unknown | Honoraria, consulting and research funding.((Parker, J. L., Kuzulugil, S. S., Pereverzev, K., Mac, S., Lopes, G., Shah, Z., Weerasinghe, A., Rubinger, D., Falconi, A., Bener, A., Caglayan, B., Tangri, R., & Mitsakakis, N. (2021). //Does biomarker use in oncology improve clinical trial failure risk? A large‐scale analysis.// Cancer Medicine, 10(6), 1955–1963. https://doi.org/10.1002/cam4.3732)) | |
| | [[:Allison McGeer]] | Various | Unknown | Personal fees, research grants, advisory board fees.((Yau, K., Abe, K. T., Naimark, D., Oliver, M. J., Perl, J., Leis, J. A., Bolotin, S., Tran, V., Mullin, S. I., Shadowitz, E., Gonzalez, A., Sukovic, T., Garnham-Takaoka, J., de Launay, K. Q., Takaoka, A., Straus, S. E., McGeer, A. J., Chan, C. T., Colwill, K., . . . Hladunewich, M. A. (2021). //Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.// JAMA Network Open, 4(9), e2123622. https://doi.org/10.1001/jamanetworkopen.2021.23622)) ((Abe, K. T., Hu, Q., Mozafarihashjin, M., Samson, R., Manguiat, K., Robinson, A., Rathod, B., Hardy, W. R., Wang, J. H., Iskilova, M., Pasculescu, A., Fazel-Zarandi, M., Li, A., Paterson, A., Chao, G., Green, K., Gilbert, L., Barati, S., Haq, N., . . . Gingras, A. C. (2021). //Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers.// medRxiv. Published. https://doi.org/10.1101/2021.08.06.21261721)) | | | [[:Allison McGeer]] | Various | Unknown | Personal fees, research grants, advisory board fees.((Yau, K., Abe, K. T., Naimark, D., Oliver, M. J., Perl, J., Leis, J. A., Bolotin, S., Tran, V., Mullin, S. I., Shadowitz, E., Gonzalez, A., Sukovic, T., Garnham-Takaoka, J., de Launay, K. Q., Takaoka, A., Straus, S. E., McGeer, A. J., Chan, C. T., Colwill, K., . . . Hladunewich, M. A. (2021). //Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.// JAMA Network Open, 4(9), e2123622. https://doi.org/10.1001/jamanetworkopen.2021.23622)) ((Abe, K. T., Hu, Q., Mozafarihashjin, M., Samson, R., Manguiat, K., Robinson, A., Rathod, B., Hardy, W. R., Wang, J. H., Iskilova, M., Pasculescu, A., Fazel-Zarandi, M., Li, A., Paterson, A., Chao, G., Green, K., Gilbert, L., Barati, S., Haq, N., . . . Gingras, A. C. (2021). //Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers.// medRxiv. Published. https://doi.org/10.1101/2021.08.06.21261721)) | |
| | [[:Menaka Pai]] | Advisory Board | Unknown (possibly pro bono) | Attended at least one advisory committee meeting.((Pai, M. (2021, August 27). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220108230011/https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Drugs-and-Biologics-Clinical-Practice-Guidelines-Working-Group_Menaka-Pai_20210827.pdf)) ((//Contributor disclosures.// UpToDate. Retrieved January 27, 2022, from https://archive.ph/6XqtC)) | | | [[:Menaka Pai]] | Advisory Board | Unknown (possibly pro bono) | Attended at least one advisory committee meeting.((Pai, M. (2021, August 27). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220108230011/https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Drugs-and-Biologics-Clinical-Practice-Guidelines-Working-Group_Menaka-Pai_20210827.pdf)) ((//Contributor disclosures.// UpToDate. Retrieved January 27, 2022, from https://archive.ph/6XqtC)) | |
| ^ Name ^ Type ^ Amount ^ Description ^ | ^ Name ^ Type ^ Amount ^ Description ^ |
| | [[:CNBC]] | Advertising | Unknown | Paid editorial promoting Pfizer's mRNA vaccine technology.((Pfizer. (2021, October 1). //For Pfizer, a COVID-19 vaccine may just be the beginning for the potential revolutionary promise of mRNA technology.// CNBC; NBCUniversal. https://archive.ph/N7oE7)) ((CNBC (@CNBC). (2021, October 4). //After delivering the first COVID-19 vaccine, Pfizer is uniquely positioned to advance mRNA, which could be a breakthrough for other infectious diseases, genetic diseases and cancer. [Tweet].// Twitter. https://archive.ph/BbvAN)) | | | [[:CNBC]] | Advertising | Unknown | Paid editorial promoting Pfizer's mRNA vaccine technology.((Pfizer. (2021, October 1). //For Pfizer, a COVID-19 vaccine may just be the beginning for the potential revolutionary promise of mRNA technology.// CNBC; NBCUniversal. https://archive.ph/N7oE7)) ((CNBC (@CNBC). (2021, October 4). //After delivering the first COVID-19 vaccine, Pfizer is uniquely positioned to advance mRNA, which could be a breakthrough for other infectious diseases, genetic diseases and cancer. [Tweet].// Twitter. https://archive.ph/BbvAN)) | |
| | [[:CNN]] | Sponsorship | Unknown | "CNN Tonight is brought to you by Pfizer." ((Farris, A. (2021, October 21). //Pfizer Apparently Sponsors Everything On Mainstream Media.// OutKick. https://archive.ph/lh8FJ)) | | | [[:CNN]] | Sponsorship | Unknown | "CNN Tonight is brought to you by Pfizer."((Farris, A. (2021, October 21). //Pfizer Apparently Sponsors Everything On Mainstream Media.// OutKick. https://archive.ph/lh8FJ)) | |
| | [[:National Geographic]] | Advertising | Unknown | COVID-19 mRNA vaccine documentary paid for by Pfizer, who collaborated on the content.((Pfizer Inc. (@Pfizer). (2021, March 15). //We’re incredibly #PfizerProud of all of our colleagues who worked tirelessly on the history-making undertaking of developing the first Covid-19 vaccine. Follow the journey of the past year with the special @NatGeo documentary "Mission Possible- The Race for a Vaccine. [Tweet].// Twitter. https://archive.ph/x8B7g)) | | | [[:National Geographic]] | Advertising | Unknown | COVID-19 mRNA vaccine documentary paid for by Pfizer, who collaborated on the content.((Pfizer Inc. (@Pfizer). (2021, March 15). //We’re incredibly #PfizerProud of all of our colleagues who worked tirelessly on the history-making undertaking of developing the first Covid-19 vaccine. Follow the journey of the past year with the special @NatGeo documentary "Mission Possible- The Race for a Vaccine. [Tweet].// Twitter. https://archive.ph/x8B7g)) | |
| |
| |
| ^ Name ^ Type ^ Amount ^ Description ^ | ^ Name ^ Type ^ Amount ^ Description ^ |
| | | [[:ABC Global Alliance]] | Sponsorship | - | Main sponsor through unrestricted grants and sponsorships.((//Partners.// The Arthritis Society. Retrieved May 14, 2022, from https://archive.ph/w1Ecc)) | |
| | [[:Ansell]] | Products | Unknown | Purchasing of large quantities of rubber gloves.((Evans, S. (2021, February 15). //Ansell doubles production as extraordinary demand to stay.// Australian Financial Review. | | [[:Ansell]] | Products | Unknown | Purchasing of large quantities of rubber gloves.((Evans, S. (2021, February 15). //Ansell doubles production as extraordinary demand to stay.// Australian Financial Review. |
| https://archive.ph/B0VJk)) | | https://archive.ph/B0VJk)) | |
| | [[:Life Sciences British Columbia]] | Sponsorship | - | Platinum Sponsor and Member Organization.((//Pfizer Canada Inc.// Life Sciences British Columbia. Retrieved April 24, 2022, from https://archive.ph/3yn0E)) | | | [[:Life Sciences British Columbia]] | Sponsorship | - | Platinum Sponsor and Member Organization.((//Pfizer Canada Inc.// Life Sciences British Columbia. Retrieved April 24, 2022, from https://archive.ph/3yn0E)) | |
| | [[:National Health Council]] | Membership | - | Member organization.((//Our Members.// National Health Council. Retrieved April 6, 2022, from https://web.archive.org/web/20220406081753/https://nationalhealthcouncil.org/members/?m_cat=74&m_key=)) | | | [[:National Health Council]] | Membership | - | Member organization.((//Our Members.// National Health Council. Retrieved April 6, 2022, from https://web.archive.org/web/20220406081753/https://nationalhealthcouncil.org/members/?m_cat=74&m_key=)) | |
| | | [[:National Press Foundation]] | Funding | $100,000 + | Chairman's Circle, alongside the [[:Bill & Melinda Gates Foundation]].((//Our Funders.// (2010, September 26). Wayback Machine; National Press Foundation. https://web.archive.org/web/20100926162431/http://nationalpress.org/about/our-funders/)) | |
| | [[:New Brunswick Health Research Foundation]] | Sponsor | - | Sponsor for the 9th Annual New Brunswick Health Research Conference in 2017.((//Annual report 2016–2017.// (2017). New Brunswick Health Research Foundation. https://web.archive.org/web/20220328032102/https://nbhrf.com/wp-content/uploads/2021/11/NBHRF-Annual-Report-English-Cover.cdr_.pdf)) | | | [[:New Brunswick Health Research Foundation]] | Sponsor | - | Sponsor for the 9th Annual New Brunswick Health Research Conference in 2017.((//Annual report 2016–2017.// (2017). New Brunswick Health Research Foundation. https://web.archive.org/web/20220328032102/https://nbhrf.com/wp-content/uploads/2021/11/NBHRF-Annual-Report-English-Cover.cdr_.pdf)) | |
| | [[:North Bay Regional Health Centre]] | Donation | $5,000.00 - $9,999.00 | Lifetime donations to the NBRHC Foundation as of March 31, 2019.((North Bay Regional Health Centre Foundation. (2019). //NBRHC 2019 Donor Wall List.// Internet Archive. North Bay Regional Health Sciences Centre Foundation. https://archive.org/details/2019-donor-wall-list/mode/2up)) | | | [[:North Bay Regional Health Centre]] | Donation | $5,000.00 - $9,999.00 | Lifetime donations to the NBRHC Foundation as of March 31, 2019.((North Bay Regional Health Centre Foundation. (2019). //NBRHC 2019 Donor Wall List.// Internet Archive. North Bay Regional Health Sciences Centre Foundation. https://archive.org/details/2019-donor-wall-list/mode/2up)) | |
| ==== Allegations of Funding Terrorism ==== | ==== Allegations of Funding Terrorism ==== |
| There is currently a lawsuit against Pfizer over claims of funding terrorism in Iraq.((January 5, 2022 | Inquirer.net | [[https://newsinfo.inquirer.net/1536247/us-court-revives-lawsuit-against-pfizer-others-on-iraq-terrorism-funding-claims|US court revives lawsuit against Pfizer, others on Iraq terrorism funding claims]])) | There is currently a lawsuit against Pfizer over claims of funding terrorism in Iraq.((January 5, 2022 | Inquirer.net | [[https://newsinfo.inquirer.net/1536247/us-court-revives-lawsuit-against-pfizer-others-on-iraq-terrorism-funding-claims|US court revives lawsuit against Pfizer, others on Iraq terrorism funding claims]])) |
| | |
| | ==== Academic Partners UCSF ==== |
| | |
| | May 29, 2013 |
| | Pfizer’s Centers for Therapeutic Innovation Partners with UCSF to Expand Drug Discovery Capabilities |
| | |
| | UCSF Becomes First Partner in Both Small-Molecule and Biologics Discovery |
| | |
| | By Kristen Bole {{ :pharmaceutical_companies:pfizer_2013_ucsf.png?400|}} |
| | |
| | Pfizer has announced the expansion of its [[:Centers for Therapeutic Innovation]] (CTI) into the development of small-molecule drug candidates through a partnership with UC San Francisco. |
| | |
| | This partnership provides investigators from UCSF with access to Pfizer’s industry-leading small-molecule drug development capabilities, working side-by-side with Pfizer scientists with the goal of jointly translating promising basic research into drug candidates that have the potential to bring innovative new therapies to patients. |
| | |
| | “This expansion is part of the natural evolution of CTI as we continue to drive forward the next generation of innovative, differentiated medicines. With Pfizer’s strong heritage in medicinal chemistry, it makes perfect sense to expand CTI’s mandate to include small-molecule projects,” said Jose Carlos Gutierrez-Ramos, PhD, group senior vice president and head of biotherapeutics R&D at Pfizer. “UCSF has been a great collaborator and has an established history in this area. I am confident that together we are better positioned to deliver faster and more efficient drug discovery with the aim of bringing new medicines to patients more quickly. |
| | |
| | The collaboration builds upon an October 2010 agreement between CTI and UCSF in large-molecule – also called biologics – discovery, with both agreements aiming to accelerate the translation of biomedical research into new medications and therapies. ((https://web.archive.org/web/20210630074451/https://www.ucsf.edu/news/2013/05/106276/pfizers-centers-therapeutic-innovation-partners-ucsf-expand-drug-discovery)) |
| | |
| | ==== Pfizer Recommends Hydroxychloroquine for Covid-19 ==== |
| | {{ :pharmaceutical_companies:pfizer_hcq_treats_covid_-_mechanism_page.png?600|}} |
| | See Ashmedai article at Substack or [[:Hydroxychloroquine]] in wiki. ((https://ashmedai.substack.com/p/pfizer-still-recommends-hydroxychloroquine)) |
| | |
| | TO give some added perspective, the FDA’s evidence that HCQ does NOT work is EXCLUSIVELY regarding hospitalized covid patients - precisely the same folks for which Pfizer is recommending HCQ!! |
| | |
| | Pfizer is so transcendently theophanic that its pronouncements are the embodiment of the scientific method, as we all witnessed when the CDC Director herself understood that a CNN report of Pfizer’s proclamation of its vaccine trial’s results amounted to an official communique of eternally settled Scientific fact. |
| | {{ :pharmaceutical_companies:pfizer_hcq_treats_covid_text_box_large.png?400|}} |
| | |
| | |
| | If Pfizer declares that HCQ works to treat covid - we can limit their revised catechism to late stage severe covid if you really want to be nitpicky here - then doesn’t this mean that the formerly heretical position that HCQ can treat covid is now fundamental doctrinal truth?? |
| | |
| | Alternatively, if we can’t trust Pfizer, the oracle of science, who can we trust???? |
| | |
| | Pfizer pdf Wayback((https://web.archive.org/web/20221213102408/https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/343db662-0565-4062-8956-00ddd5bb4fbb/COVID-19%20Antiviral%20-%202.%20Clinical%20Presentation-Proactive.pdf)) |
